GSK's Taflinar pockets breakthrough label

Share this article:

GlaxoSmithKline's Tafinlar garnered additional FDA attention Monday when the regulator granted the drug Breakthrough Therapy status for patients with metastatic BRAF V600E mutation-positive non-small-cell lung cancer who have already undergone platinum-containing chemotherapy.

Phase-II data helped secure the designation, which accelerates the regulatory review process. The FDA approved this same drug January 9 for use with Mekinist among patients with unresectable metastatic melanoma with BRAF V600 or V600K mutation or for treating metastatic melanoma with either of these mutations.

Tafinlar was approved last May for use as a single-agent oral therapy in treating unresectable or metastatic melanoma in patients with the BRAF V600 or V600K mutation. And this month, the FDA also sanctioned single-pill combination use of Tafinlar and Mekinist, GSK's other drug for patients whose melanoma cells have the V600E or V600K mutation in the BRAF gene.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.